Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (191-200 of 436) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|August 18, 2020
Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutationsCurtis Lachowiez, Sarah Bannon, Sanam Loghavi, et al.
Frontiers in Oncology|May 27, 2021
Immunotherapy in Acute Myeloid Leukemia: Where We StandAlessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Leukemia & Lymphoma|September 5, 2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemiaYue Wei, Hong Zheng, Pamela Pennington Lockyer, et al.
Leukemia & Lymphoma|October 4, 2017
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage settingPrajwal Boddu, Abdul Rashid Shah, Gautam Borthakur, et al.
Leukemia & Lymphoma|February 19, 2026
Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN)Amritpal Singh, Naval Daver, Sanam Loghavi, et al.
American Journal of Hematology|February 22, 2021
A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemiaNaval Daver, Amandeep Salhotra, Joseph M Brandwein, et al.
British Journal of Haematology|October 15, 2014
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosisNaval Daver, Hagop Kantarjian, Guido Marcucci, et al.
Leukemia & Lymphoma|January 18, 2018
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemiaPrajwal Boddu, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia Research|May 14, 2024
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPNGuillermo Montalban-Bravo, Elias Jabbour, Kelly Chien, et al.
American Journal of Hematology|April 6, 2022
Prediction of survival with intensive chemotherapy in acute myeloid leukemiaKoji Sasaki, Farhad Ravandi, Tapan Kadia, et al.
Pageof 44

Showing results (191-200 of 436) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|August 18, 2020
Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutationsCurtis Lachowiez, Sarah Bannon, Sanam Loghavi, et al.
Frontiers in Oncology|May 27, 2021
Immunotherapy in Acute Myeloid Leukemia: Where We StandAlessandro Isidori, Claudio Cerchione, Naval Daver, et al.
Leukemia & Lymphoma|September 5, 2022
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemiaYue Wei, Hong Zheng, Pamela Pennington Lockyer, et al.
Leukemia & Lymphoma|October 4, 2017
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage settingPrajwal Boddu, Abdul Rashid Shah, Gautam Borthakur, et al.
Leukemia & Lymphoma|February 19, 2026
Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN)Amritpal Singh, Naval Daver, Sanam Loghavi, et al.
American Journal of Hematology|February 22, 2021
A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemiaNaval Daver, Amandeep Salhotra, Joseph M Brandwein, et al.
British Journal of Haematology|October 15, 2014
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosisNaval Daver, Hagop Kantarjian, Guido Marcucci, et al.
Leukemia & Lymphoma|January 18, 2018
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemiaPrajwal Boddu, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia Research|May 14, 2024
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPNGuillermo Montalban-Bravo, Elias Jabbour, Kelly Chien, et al.
American Journal of Hematology|April 6, 2022
Prediction of survival with intensive chemotherapy in acute myeloid leukemiaKoji Sasaki, Farhad Ravandi, Tapan Kadia, et al.
Pageof 44